Sarcoma
Sarcoma is not one disease but a collection of more than a hundred subtypes, many of them individually rare. Subtype identification is the decisive step, and specialist sarcoma pathology review is a recurring theme in the discussion of these tumours.
Disease categories
Major disease categories
- Soft tissue sarcoma
- Bone sarcoma
- Gastrointestinal stromal tumours
- Rhabdomyosarcoma
- Ewing sarcoma
- Osteosarcoma
- Liposarcoma
- Leiomyosarcoma
Molecular
Molecular considerations
Many sarcoma subtypes are defined by characteristic fusions — EWSR1 rearrangements in Ewing sarcoma, SS18 rearrangement in synovial sarcoma, FUS and DDIT3 in myxoid liposarcoma. Gastrointestinal stromal tumours are defined by KIT or PDGFRA alterations, with wild-type disease raising SDH-deficiency. MDM2 amplification distinguishes well-differentiated and dedifferentiated liposarcoma.
Markers commonly discussed in sarcoma
- EWSR1 fusions
- SS18 rearrangement
- KIT / PDGFRA
- MDM2 amplification
- SDH deficiency
- NTRK fusions
- ALK (inflammatory myofibroblastic tumour)
Not exhaustive, and not every marker is assessed in every patient. Which of these is relevant depends on the individual case and should be discussed with the treating team.
Testing
Genomic testing considerations
Fusion detection is critical in sarcoma, and an assay that detects only sequence variants may miss the defining alteration entirely.
Germline
Germline considerations
Germline assessment is discussed particularly in young patients and where Li-Fraumeni syndrome or retinoblastoma predisposition is a consideration.
Molecular monitoring
ctDNA and liquid biopsy considerations
Investigational in most sarcoma subtypes.
Single-cell & computation
Single-cell and algorithmic approaches
Sarcoma is defined, in many of its subtypes, by a single fusion event — which makes breakpoint detection the central algorithmic problem rather than variant calling. Pipelines have to be built around RNA fusion detection and structural variant analysis, because a sequence-variant panel will report a fusion-driven sarcoma as unremarkable. Single-cell RNA sequencing is used to characterise differentiation state and the stromal and immune compartments, which differ markedly across entities that share a name. Methylation-based classification is increasingly used where the histological diagnosis is contested, which in this disease group is often.
In practice
What a review of this disease typically surfaces
Subtype confirmation is the single highest-value step, and specialist sarcoma pathology review changes it more often than in most solid tumours. The second recurring finding is fusion testing that was never performed, or performed on an assay incapable of detecting fusions, in a subtype defined by one. For gastrointestinal stromal tumours, the specific KIT or PDGFRA exon is frequently absent from the record despite determining the treatment discussion.
Patterns observed across precision oncology case reviews. Every case differs; these are the questions worth checking, not conclusions about any individual patient.
Decisions
Treatment decision questions
Questions worth raising with a treating team when a decision is being made:
- Has the diagnosis been reviewed by a specialist sarcoma pathology service?
- Has fusion testing been performed where the subtype requires it?
- For gastrointestinal stromal tumours, is the specific KIT or PDGFRA alteration recorded?
Resistance
Resistance and recurrence questions
- For gastrointestinal stromal tumours, has a secondary resistance alteration been sought?
- Has the diagnosis been revisited if behaviour is atypical for the stated subtype?
Trials
Clinical trial considerations
Subtype-specific and fusion-specific trials form a substantial part of the sarcoma landscape; international search is often necessary.
When a precision oncology review may help
A review is most useful where the standard pathway has been exhausted or where the picture is more complicated than a protocol accounts for — rare presentations, treatment resistance, complex or apparently contradictory molecular findings, or a decision between several defensible options.
The output is a structured analysis and a set of questions for the treating team. It is not treatment, and it does not replace the treating oncologist.